Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2011
We read with great interest the recently published article by Nissen and Wolski,1 which updated their previous meta-analysis2 of risk for myocardial infarction and cardiovascular mortality relating to the diabetes drug rosiglitazone. The authors conclude that rosiglitazone statistically significantly increases risk of myocardial infarction relative to comparators by reporting an odds ratio of 1.28, with a 95% confidence interval (CI) of 1.02 to 1.63 and a significant P value of .04, while finding no significant difference in cardiovascular mortality (P = .86 in their current analysis, compared with P = .06 in their previous report).
Claggett B, Wei L. Analytical Issues Regarding Rosiglitazone Meta-analysis. Arch Intern Med. 2011;171(2):179-180. doi:10.1001/archinternmed.2010.508